SG10201707763PA - FGF21 Mutants And Uses Thereof - Google Patents
FGF21 Mutants And Uses ThereofInfo
- Publication number
- SG10201707763PA SG10201707763PA SG10201707763PA SG10201707763PA SG10201707763PA SG 10201707763P A SG10201707763P A SG 10201707763PA SG 10201707763P A SG10201707763P A SG 10201707763PA SG 10201707763P A SG10201707763P A SG 10201707763PA SG 10201707763P A SG10201707763P A SG 10201707763PA
- Authority
- SG
- Singapore
- Prior art keywords
- fgf21 mutants
- fgf21
- mutants
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17573609P | 2009-05-05 | 2009-05-05 | |
US28511809P | 2009-12-09 | 2009-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201707763PA true SG10201707763PA (en) | 2017-11-29 |
Family
ID=42455356
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011080637A SG175861A1 (en) | 2009-05-05 | 2010-05-04 | Fgf21 mutants and uses thereof |
SG10201707763PA SG10201707763PA (en) | 2009-05-05 | 2010-05-04 | FGF21 Mutants And Uses Thereof |
SG10201402038WA SG10201402038WA (en) | 2009-05-05 | 2010-05-04 | FGF21 Mutants And Uses Thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011080637A SG175861A1 (en) | 2009-05-05 | 2010-05-04 | Fgf21 mutants and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201402038WA SG10201402038WA (en) | 2009-05-05 | 2010-05-04 | FGF21 Mutants And Uses Thereof |
Country Status (37)
Country | Link |
---|---|
US (4) | US8188040B2 (fr) |
EP (3) | EP2427208B1 (fr) |
JP (1) | JP5823954B2 (fr) |
KR (2) | KR20180014235A (fr) |
CN (2) | CN107188950B (fr) |
AR (1) | AR076541A1 (fr) |
AU (1) | AU2010246108B2 (fr) |
BR (1) | BRPI1011404B1 (fr) |
CA (1) | CA2760196C (fr) |
CL (1) | CL2011002768A1 (fr) |
CO (1) | CO6470863A2 (fr) |
CR (1) | CR20110639A (fr) |
DK (1) | DK3248610T3 (fr) |
EA (1) | EA021425B1 (fr) |
ES (2) | ES2632742T3 (fr) |
FI (1) | FI3248610T3 (fr) |
HK (1) | HK1247134A1 (fr) |
HR (1) | HRP20240135T1 (fr) |
HU (1) | HUE065036T2 (fr) |
IL (2) | IL215937A (fr) |
JO (1) | JO3469B1 (fr) |
LT (1) | LT3248610T (fr) |
MA (1) | MA33716B1 (fr) |
MX (1) | MX2011011709A (fr) |
MY (1) | MY156542A (fr) |
NZ (1) | NZ596037A (fr) |
PE (2) | PE20120358A1 (fr) |
PH (1) | PH12015502433A1 (fr) |
PL (1) | PL3248610T3 (fr) |
PT (1) | PT3248610T (fr) |
RS (1) | RS65153B1 (fr) |
SG (3) | SG175861A1 (fr) |
SI (1) | SI3248610T1 (fr) |
TW (2) | TWI436776B (fr) |
UY (2) | UY32607A (fr) |
WO (1) | WO2010129503A1 (fr) |
ZA (1) | ZA201108371B (fr) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
KR101651703B1 (ko) | 2008-10-10 | 2016-08-26 | 암젠 인크 | Fgf21 돌연변이체 및 이의 용도 |
PE20120358A1 (es) * | 2009-05-05 | 2012-04-26 | Amgen Inc | Mutantes fgf21 y usos de los mismos |
CA2760674A1 (fr) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Mutants de fgf21 et leurs utilisations |
US8324160B2 (en) | 2009-06-17 | 2012-12-04 | Amgen Inc. | Chimeric polypeptides and uses thereof |
MX2012006397A (es) | 2009-12-02 | 2012-11-30 | Amgen Inc | PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA. |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
US9517264B2 (en) | 2010-04-15 | 2016-12-13 | Amgen Inc. | Human FGF receptor and β-Klotho binding proteins |
EP2558115B1 (fr) | 2010-04-16 | 2019-07-31 | The Salk Institute for Biological Studies | Procédés de traitement de troubles métaboliques utilisant le fgf |
CA2835101A1 (fr) * | 2011-05-10 | 2012-11-15 | Amgen Inc. | Procede d'identification de composes qui modulent specifiquement l'interaction de fgfr1 et de .beta.-klotho |
KR102077721B1 (ko) | 2011-07-01 | 2020-02-14 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법 |
MX2014002260A (es) | 2011-08-31 | 2014-08-18 | Amgen Inc | Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1. |
US9458214B2 (en) * | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
US9006400B2 (en) * | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
AU2015202304C1 (en) * | 2011-09-26 | 2017-03-09 | Novartis Ag | Fusion proteins for treating metabolic disorders |
AR087973A1 (es) | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
WO2013131091A1 (fr) | 2012-03-02 | 2013-09-06 | New York University | Protéines chimères fgf21 ayant une affinité de liaison augmentée pour le bêta-klotho dans le traitement du diabète de type ii, de l'obésité et des troubles métaboliques apparentés |
US9550819B2 (en) | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
EP2849567B1 (fr) | 2012-05-17 | 2022-03-23 | Extend Biosciences, Inc. | Véhicules destinés à améliorer l'administration des médicaments |
US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
US9474785B2 (en) | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子21蛋白質 |
EA201492064A1 (ru) | 2012-06-11 | 2015-02-27 | Эли Лилли Энд Компани | Варианты фактора роста фибробластов 21 |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
NZ630484A (en) | 2012-11-28 | 2017-04-28 | Ngm Biopharmaceuticals Inc | Compositions and methods for treatment of metabolic disorders and diseases |
KR20230164238A (ko) | 2012-12-27 | 2023-12-01 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법 |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
WO2014130659A1 (fr) | 2013-02-22 | 2014-08-28 | New York University | Protéines chimères du facteur de croissance des fibroblastes 23 et méthodes d'utilisation |
WO2014149699A1 (fr) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Protéine bifonctionnelle |
EP3057605A1 (fr) | 2013-10-18 | 2016-08-24 | Novartis AG | Méthodes de traitement du diabete et de troubles associés |
JP6621752B2 (ja) | 2013-10-21 | 2019-12-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 変異した線維芽細胞増殖因子(fgf)1および使用方法 |
KR102178945B1 (ko) | 2013-10-28 | 2020-11-13 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 암 모델 및 관련 방법 |
HUE050279T2 (hu) | 2014-01-24 | 2020-11-30 | Ngm Biopharmaceuticals Inc | Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei |
US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
MX2016012219A (es) | 2014-03-25 | 2016-12-16 | Regeneron Pharma | Agonistas de receptor fgf21 y usos del mismo. |
CN103923207B (zh) * | 2014-04-08 | 2016-03-09 | 东北农业大学 | 一种fgf-21突变体蛋白的制备及其在治疗非酒精性脂肪肝中的应用 |
WO2015183890A2 (fr) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Méthodes et compositions pour le traitement de maladies et de troubles métaboliques |
AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
PE20170771A1 (es) | 2014-07-30 | 2017-07-04 | Ngm Biopharmaceuticals Inc | Composiciones y metodos de uso para tratar trastornos metabolicos |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
CA2964463C (fr) | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Conjugues de vitamine d therapeutiques |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
JP6949711B2 (ja) | 2014-10-23 | 2021-10-20 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | ペプチドバリアントを含む医薬組成物及びその使用方法 |
MX357994B (es) | 2014-10-31 | 2018-08-01 | Ngm Biopharmaceuticals Inc | Composiciones y metodos de uso para tratar trastornos metabolicos. |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
SI3236991T1 (sl) | 2014-12-23 | 2019-09-30 | Novo Nordisk A/S | Derivati FGF21 in njihova uporaba |
KR20160088656A (ko) | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
US20180071981A1 (en) * | 2015-03-31 | 2018-03-15 | The Regents Of The University Of California | System and method for tunable patterning and assembly of particles via acoustophoresis |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
KR20180035852A (ko) * | 2015-08-03 | 2018-04-06 | 노파르티스 아게 | Fgf21-연관 장애를 치료하는 방법 |
AU2016332062A1 (en) * | 2015-10-01 | 2018-04-26 | Amgen Inc. | Treatment of bile acid disorders |
BR112018008805A8 (pt) | 2015-10-28 | 2019-02-26 | Yuhan Corp | proteínas de função dupla e composição farmacêutica que compreende a mesma |
RU2741087C2 (ru) | 2015-10-28 | 2021-01-22 | Юхан Корпорейшн | Слитые с fgf21 белки длительного действия и содержащая их фармацевтическая композиция |
CA3002400A1 (fr) | 2015-10-30 | 2017-05-04 | Salk Institute For Biological Studies | Traitement de l'hyperglycemie induite par des steroides avec des analogues de facteur de croissance des fibroblastes (fgf) 1 |
ES2871036T3 (es) | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Método para el tratamiento de trastornos relacionados con ácidos biliares |
TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Fgf21變異體 |
IL261666B1 (en) | 2016-03-31 | 2024-05-01 | Ngm Biopharmaceuticals Inc | Related proteins and methods of using them |
WO2018032638A1 (fr) | 2016-08-19 | 2018-02-22 | 安源医药科技(上海)有限公司 | Peptide de liaison pour la construction d'une protéine de fusion |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
CN107759696A (zh) | 2016-08-19 | 2018-03-06 | 安源医药科技(上海)有限公司 | 人白介素7融合蛋白及其制备方法 |
US20190201491A1 (en) * | 2016-08-22 | 2019-07-04 | Elanco Us Inc. | Bovine fibroblast growth factor 21 and ketosis in dairy cattle |
AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
JP7328891B2 (ja) | 2016-11-10 | 2023-08-17 | ユーハン・コーポレイション | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |
WO2018115401A1 (fr) | 2016-12-22 | 2018-06-28 | Sanofi | Combinaisons d'agonistes du composé fgf21/agoniste du glp-1r ayant un rapport d'activité optimisé |
EA201992516A1 (ru) | 2017-04-21 | 2020-04-09 | Юхан Корпорейшн | Способ получения бифункциональных белков и их производных |
CN107056925B (zh) | 2017-04-28 | 2022-01-14 | 中国科学院合肥物质科学研究院 | 人fgf21突变体、其制备方法及用途 |
EP3701046A1 (fr) * | 2017-10-27 | 2020-09-02 | SVAR Life Science AB | Peptides rapporteurs sécrétés pour optimiser des dosages à base de cellules pour une analyse sur des plateformes d'immunoessais |
CN110128525B (zh) * | 2018-02-08 | 2022-08-26 | 广东东阳光药业有限公司 | Fgf21变体、融合蛋白及其应用 |
KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
KR20210137093A (ko) * | 2019-03-05 | 2021-11-17 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 폴리펩티드 분자 및 이의 적용 |
CN111944055B (zh) | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
CN113583142A (zh) * | 2021-08-20 | 2021-11-02 | 赣江中药创新中心 | 双靶点融合蛋白、编码基因、载体或宿主细胞及其应用与表达和纯化方法 |
WO2023035817A1 (fr) * | 2021-09-08 | 2023-03-16 | 北京志道生物科技有限公司 | Protéine mutante fgf21 et son utilisation |
CN117813323A (zh) | 2021-09-23 | 2024-04-02 | 江苏恒瑞医药股份有限公司 | 抗klb抗体及用途 |
WO2023064808A1 (fr) | 2021-10-13 | 2023-04-20 | Akero Therapeutics, Inc. | Compositions pharmaceutiques d'efruxiol |
WO2024059507A1 (fr) | 2022-09-12 | 2024-03-21 | Akero Therapeutics, Inc. | Polypeptides mutants de fgf21 |
CN116675780A (zh) * | 2023-06-02 | 2023-09-01 | 东北农业大学 | 犬成纤维细胞生长因子21融合蛋白制备及其在治疗特应性皮炎中的用途 |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
EP0088046B1 (fr) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipides en phase aqueuse |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
CA1310924C (fr) | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Systeme d'administration d'un medicament a l'aide de particules infectieuses |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5288855A (en) | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
SG72657A1 (en) | 1989-07-06 | 2000-05-23 | Univ California | Receptors for fibroblast growth factors |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
UA42675C2 (uk) | 1989-12-22 | 2001-11-15 | Апплайд Рєзєч Сістемз, Арс Холдінг Н.В. (Антільські Острови) | Спосіб активації гена, що в нормі транскрипційно мовчить, з геному еукаріотичної клітинної лінії, спосіб модифікації характеристик експресії гена з геному еукаріотичної клітинної лінії, диференційована еукаріотична клітинна лінія (варіанти), днк-конструкт |
WO1991010470A1 (fr) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Dispositifs et procedes d'apport ameliore de facteurs actifs |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US5672510A (en) | 1990-01-19 | 1997-09-30 | Genetic Therapy, Inc. | Retroviral vectors |
ATE243253T1 (de) | 1990-07-06 | 2003-07-15 | Rhone Poulenc Rorer Internat H | Rezeptoren der wachstumsfaktoren aus fibroblasten |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5217889A (en) | 1990-10-19 | 1993-06-08 | Roninson Igor B | Methods and applications for efficient genetic suppressor elements |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5229501A (en) | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
IL100219A0 (en) | 1991-12-02 | 1992-09-06 | Yeda Res & Dev | Variable region within fibroblast growth factor receptors that confers ligand specificity |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
US5364791A (en) | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
CA2136439A1 (fr) | 1992-06-18 | 1994-01-06 | Michael Philip Nova | Methode de detection des maladies neoplasiques |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
GB9313210D0 (en) * | 1993-06-25 | 1993-08-11 | Sandoz Ltd | Novel combinations |
US6664107B1 (en) | 1993-05-26 | 2003-12-16 | Ontario Cancer Institute, University Health Network | CD45 disrupted nucleic acid |
CA2161015A1 (fr) | 1993-05-26 | 1994-12-08 | Tak Wah Mak | Absence d'expression d'isoformes cd45 specifiques chez des mammiferes transgeniques |
US5589362A (en) | 1993-06-14 | 1996-12-31 | Basf Aktiengesellschaft | Tetracycline regulated transcriptional modulators with altered DNA binding specificities |
US5654168A (en) | 1994-07-01 | 1997-08-05 | Basf Aktiengesellschaft | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
ES2140359T1 (es) | 1993-06-14 | 2000-03-01 | Basf Ag | Control preciso de expresion genetica en celulas eucarioticas mediante promotores que responden a la tetaciclina. |
US5469743A (en) * | 1993-06-24 | 1995-11-28 | Zorn; Roger H. | Dynamic surface wave roll inspection device |
EP1179350A3 (fr) | 1993-08-12 | 2003-01-02 | Cytotherapeutics, Inc. | Système cellulaire encapsulé pour implantation dans le SNC hunain |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5654166A (en) * | 1994-11-09 | 1997-08-05 | Kurth; Gerhard P. | Process of preparing hormone-free bovine cartilage for dosage form |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
EP0822830B1 (fr) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Anticorps anti-IL-8 dérivés de xenosouris immunisées |
JPH11506319A (ja) | 1995-05-26 | 1999-06-08 | ゼネカ・リミテッド | エクジソンレセプターを含む遺伝子スイッチ |
US5849303A (en) | 1995-06-07 | 1998-12-15 | American Home Products Corporation | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection |
EP0832269A1 (fr) | 1995-06-07 | 1998-04-01 | Baylor College Of Medicine | Transporteurs d'acide nucleique servant a introduire des acides nucleiques dans une cellule |
CA2219080A1 (fr) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Regulation d'evenements biologiques fondee sur la rapamycine |
EP0888303B1 (fr) | 1996-02-28 | 2010-04-21 | ARIAD Pharmaceuticals, Inc | Derives synthetiques de rapamycine utilises comme agents de multimerisation de proteines chimeres a domaines derives de l'immunophiline |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
US6214795B1 (en) | 1996-11-12 | 2001-04-10 | Praecis Pharmaceuticals, Inc. | Peptide compounds useful for modulating FGF receptor activity |
JP4112627B2 (ja) | 1996-12-26 | 2008-07-02 | 社団法人芝蘭会 | 新規ポリペプチド、新規dnaおよび新規抗体 |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
EP0861900A1 (fr) * | 1997-02-21 | 1998-09-02 | Erziehungsdirektion Of The Canton Zurich | Détection immunologique de prions |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
US6150096A (en) * | 1997-09-26 | 2000-11-21 | Universite De Sherbrooke | Molecular markers for the diagnosis of human diseases including Crohn's disease |
IL136055A0 (en) | 1997-11-25 | 2001-05-20 | Genentech Inc | Fibroblast growth factor -19 |
US6150098A (en) | 1998-02-20 | 2000-11-21 | Amgen Inc. | Methods for identifying novel secreted mammalian polypeptides |
ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US6548634B1 (en) | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000027885A1 (fr) | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau popypeptide chimerique |
US6656728B1 (en) | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
WO2000054813A2 (fr) | 1999-03-15 | 2000-09-21 | Chiron Corporation | Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil |
CA2311201A1 (fr) | 1999-08-05 | 2001-02-05 | Genset S.A. | Sequences marqueurs exprimees et proteines humaines codees |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
AU7368100A (en) | 1999-09-10 | 2001-04-10 | Curagen Corporation | Fibroblast growth factor polypeptide and nucleic acids encoding same |
WO2001032678A1 (fr) | 1999-11-05 | 2001-05-10 | Smithkline Beecham Corporation | sbgFGF-19a |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
AU1628101A (en) | 1999-11-22 | 2001-06-04 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
US7108984B2 (en) | 2000-01-12 | 2006-09-19 | Mount Sinai School Of Medicine | Methods of identifying modulators of the FGF receptor |
WO2001049849A1 (fr) | 2000-01-05 | 2001-07-12 | Zymogenetics, Inc. | Zfgf11 : nouvel homologue de fgf |
US20020081663A1 (en) | 2000-01-05 | 2002-06-27 | Conklin Darrell C. | Novel FGF homolog ZFGF11 |
WO2001072957A2 (fr) | 2000-03-31 | 2001-10-04 | Nobuyuki Itoh | Molecules de type facteur de croissance des fibroblastes et leurs utilisations |
JP2002112772A (ja) | 2000-07-10 | 2002-04-16 | Takeda Chem Ind Ltd | 新規ポリペプチドおよびそのdna |
IL139380A0 (en) | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20040018499A1 (en) | 2001-06-06 | 2004-01-29 | Lal Preeti G | Extracellular messengers |
JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
BR0211071A (pt) | 2001-07-11 | 2004-12-21 | Maxygen Holdings Ltd | Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico |
WO2003011213A2 (fr) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Methode de traitement du diabete et de l'obesite |
US20050187150A1 (en) | 2001-10-31 | 2005-08-25 | New York University | Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds |
US20050176631A1 (en) | 2002-01-15 | 2005-08-11 | Heuer Josef G. | Method for reducing morbidity and mortality in critically ill patients |
EP1332761A1 (fr) | 2002-01-31 | 2003-08-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Agonistes des récepteurs du facteur de croissance des fibroblastes |
CA2473810A1 (fr) | 2002-01-31 | 2003-08-07 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Agonistes du fgfr |
IL149562A0 (en) | 2002-05-09 | 2002-11-10 | Prochon Ltd | Fgf variants and methods for use thereof |
JP2003334088A (ja) | 2002-05-22 | 2003-11-25 | Pharma Design Inc | ヒト由来の新規Klotho様タンパク質及びその遺伝子 |
AU2003265057A1 (en) | 2002-09-04 | 2004-03-29 | Abtech | Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy |
EP1578367A4 (fr) | 2002-11-01 | 2012-05-02 | Genentech Inc | Compositions et methodes pour le traitement de maladies liees au systeme immunitaire |
CA2510715A1 (fr) | 2002-12-20 | 2004-07-08 | Enkam Pharmaceuticals A/S | Methode de modulation de l'interaction d'un recepteur et d'un ligand |
TWI300430B (en) * | 2003-01-10 | 2008-09-01 | Ritek Corp | Optical recording medium dye and optical recording medium using thereof |
TWI304973B (en) * | 2003-01-23 | 2009-01-01 | Lg Electronics Inc | Recording medium with copy protection information formed in intermittent or alternate wobbled pits and apparatus and methods for forming, recording, and reproducing the recording medium |
WO2004083381A2 (fr) | 2003-03-13 | 2004-09-30 | Indiana University Advanced Research & Technology Institute | Polynucleotides, polypeptides et mutants des recepteurs 1 du facteur de croissance des fibroblastes |
JP2006240990A (ja) | 2003-05-15 | 2006-09-14 | Kirin Brewery Co Ltd | klothoタンパク質および抗klothoタンパク質抗体ならびにそれらの用途 |
ATE525395T1 (de) | 2003-06-12 | 2011-10-15 | Lilly Co Eli | Fusions proteine von glp-1-analoga |
PL1641483T3 (pl) | 2003-06-12 | 2008-07-31 | Lilly Co Eli | Białka fuzyjne |
WO2005019258A2 (fr) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions et methodes de traitement de maladies relatives au systeme immunitaire |
WO2005037235A2 (fr) | 2003-10-16 | 2005-04-28 | Imclone Systems Incorporated | Inhibiteurs du recepteur 1 du facteur de croissance du fibroblaste et methodes therapeutiques associees |
WO2005061712A1 (fr) | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteines a facteur de croissance fibroblastique 21 |
US20070248605A1 (en) | 2003-12-19 | 2007-10-25 | Five Prime Therapetutics, Inc. | Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention |
WO2005072769A1 (fr) | 2004-01-26 | 2005-08-11 | Eli Lilly And Company | Utilisation du fgf-21 et d'une thiazolidinedione dans le traitement du diabete de type 2 |
US7887790B2 (en) * | 2004-02-20 | 2011-02-15 | Cornell Research Foundation, Inc. | Polymers and polymer coatings |
WO2005091944A2 (fr) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Composes fgf-21 lies au glycol |
JP4505631B2 (ja) | 2004-03-31 | 2010-07-21 | 独立行政法人産業技術総合研究所 | ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物 |
DE602005016917D1 (de) | 2004-05-13 | 2009-11-12 | Lilly Co Eli | Fgf-21-fusionsproteine |
DE602005016946D1 (de) | 2004-09-02 | 2009-11-12 | Lilly Co Eli | Muteine des fibroblasten-wachstumsfaktors 21 |
US7622445B2 (en) | 2004-09-02 | 2009-11-24 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
EP1814573B1 (fr) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf) |
US7655627B2 (en) * | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
WO2006078463A2 (fr) | 2005-01-21 | 2006-07-27 | Eli Lilly And Company | Methode de traitement de maladie cardio-vasculaire |
JP2006246823A (ja) | 2005-03-11 | 2006-09-21 | Kyoto Univ | 造血因子としてのFgf21の使用 |
WO2006130527A2 (fr) | 2005-05-31 | 2006-12-07 | Novartis Ag | Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes |
US7678890B2 (en) | 2005-07-22 | 2010-03-16 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
EP1922410A2 (fr) | 2005-08-15 | 2008-05-21 | Genentech, Inc. | Disruptions et compositions géniques et procédés associés |
US7395962B2 (en) | 2005-10-28 | 2008-07-08 | United Parcel Service Of America, Inc. | Pick up notice and method of using same |
US8043833B2 (en) | 2005-10-31 | 2011-10-25 | Novo Nordisk A/S | Expression of soluble therapeutic proteins |
WO2007056789A1 (fr) | 2005-11-16 | 2007-05-24 | Dier Corporation As Trustee For The Reid Family Superannuation Trust | Nouveaux ensembles de cadres sur écrans de sécurité |
EP1996215A2 (fr) | 2006-02-28 | 2008-12-03 | Trustees Of Boston University | Régulateurs métaboliques et leurs utilisations |
EP2046384A4 (fr) | 2006-06-15 | 2009-12-02 | Fibron Ltd | Anticorps bloquant l'activation du récepteur du facteur de croissance des fibroblastes et leurs procédés d'utilisation |
WO2008011633A2 (fr) | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation de peptides par l'intermédiaire de séquences de glycosylation à liaison o |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
JP2010511382A (ja) | 2006-12-01 | 2010-04-15 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 癌関連タンパク質キナーゼ |
ATE554785T1 (de) | 2007-03-30 | 2012-05-15 | Ambrx Inc | Modifizierte fgf-21 polypeptide und ihre verwendung |
PE20090227A1 (es) | 2007-04-02 | 2009-04-03 | Genentech Inc | Composiciones farmaceuticas que comprenden agentes anti-beta-klotho |
US8697369B2 (en) | 2007-04-06 | 2014-04-15 | National Institute Of Advanced Industrial Science And Technology | Method for screening a test substance for activating a receptor associated with FGF 21 activity |
US7537903B2 (en) | 2007-04-23 | 2009-05-26 | Board Of Regents, The University Of Texas System | FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner |
EP2152295B1 (fr) | 2007-05-08 | 2018-04-18 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Protéine klotho et composés apparentés destinés au traitement du cancer |
AU2008262450A1 (en) | 2007-05-22 | 2008-12-18 | Novartis Ag | Methods of treating, diagnosing and detecting FGF21-associated disorders |
JP5563818B2 (ja) | 2007-05-29 | 2014-07-30 | 北海道公立大学法人 札幌医科大学 | 癌治療剤及び癌の治療方法 |
CN101778937A (zh) | 2007-06-04 | 2010-07-14 | 诺和诺德公司 | 使用n-乙酰葡糖胺转移酶的o-联糖基化 |
JP2010535781A (ja) | 2007-08-03 | 2010-11-25 | イーライ リリー アンド カンパニー | 肥満に対する処置 |
GB2464062A (en) | 2007-08-08 | 2010-04-07 | Foster Miller Inc | Watercraft drogue system |
US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
US20110015345A1 (en) | 2008-03-19 | 2011-01-20 | Ambrx, Inc. | Modified FGF-23 Polypeptides and Their Uses |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
WO2010006214A1 (fr) | 2008-07-09 | 2010-01-14 | Ambrx, Inc. | Anticorps de neutralisation de fgf-21 et leurs utilisations |
AU2009279806B2 (en) | 2008-08-04 | 2015-04-30 | Five Prime Therapeutics, Inc. | FGFR extracellular domain acidic region muteins |
PE20120358A1 (es) | 2009-05-05 | 2012-04-26 | Amgen Inc | Mutantes fgf21 y usos de los mismos |
CA2760674A1 (fr) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Mutants de fgf21 et leurs utilisations |
-
2010
- 2010-05-04 PE PE2011001903A patent/PE20120358A1/es active IP Right Grant
- 2010-05-04 TW TW099114297A patent/TWI436776B/zh active
- 2010-05-04 WO PCT/US2010/033478 patent/WO2010129503A1/fr active Application Filing
- 2010-05-04 ES ES10718381.6T patent/ES2632742T3/es active Active
- 2010-05-04 BR BRPI1011404-1A patent/BRPI1011404B1/pt active IP Right Grant
- 2010-05-04 UY UY0001032607A patent/UY32607A/es active IP Right Grant
- 2010-05-04 AU AU2010246108A patent/AU2010246108B2/en active Active
- 2010-05-04 NZ NZ596037A patent/NZ596037A/xx unknown
- 2010-05-04 SG SG2011080637A patent/SG175861A1/en unknown
- 2010-05-04 RS RS20240141A patent/RS65153B1/sr unknown
- 2010-05-04 HR HRP20240135TT patent/HRP20240135T1/hr unknown
- 2010-05-04 CN CN201710332729.2A patent/CN107188950B/zh active Active
- 2010-05-04 JP JP2012509888A patent/JP5823954B2/ja active Active
- 2010-05-04 MX MX2011011709A patent/MX2011011709A/es active IP Right Grant
- 2010-05-04 EP EP10718381.6A patent/EP2427208B1/fr active Active
- 2010-05-04 MY MYPI2011005289A patent/MY156542A/en unknown
- 2010-05-04 EP EP23217971.3A patent/EP4353247A2/fr active Pending
- 2010-05-04 TW TW103105224A patent/TWI560197B/zh active
- 2010-05-04 PE PE2016000015A patent/PE20160718A1/es unknown
- 2010-05-04 KR KR1020187002805A patent/KR20180014235A/ko not_active Application Discontinuation
- 2010-05-04 CN CN201080031036.6A patent/CN102655877B/zh active Active
- 2010-05-04 PT PT171676828T patent/PT3248610T/pt unknown
- 2010-05-04 DK DK17167682.8T patent/DK3248610T3/da active
- 2010-05-04 SG SG10201707763PA patent/SG10201707763PA/en unknown
- 2010-05-04 ES ES17167682T patent/ES2969528T3/es active Active
- 2010-05-04 CA CA2760196A patent/CA2760196C/fr active Active
- 2010-05-04 US US12/773,266 patent/US8188040B2/en active Active
- 2010-05-04 FI FIEP17167682.8T patent/FI3248610T3/fi active
- 2010-05-04 AR ARP100101503A patent/AR076541A1/es active IP Right Grant
- 2010-05-04 KR KR1020117029118A patent/KR101860572B1/ko active IP Right Grant
- 2010-05-04 EP EP17167682.8A patent/EP3248610B1/fr active Active
- 2010-05-04 HU HUE17167682A patent/HUE065036T2/hu unknown
- 2010-05-04 PL PL17167682.8T patent/PL3248610T3/pl unknown
- 2010-05-04 JO JOP/2010/0139A patent/JO3469B1/ar active
- 2010-05-04 LT LTEP17167682.8T patent/LT3248610T/lt unknown
- 2010-05-04 SG SG10201402038WA patent/SG10201402038WA/en unknown
- 2010-05-04 EA EA201171220A patent/EA021425B1/ru not_active IP Right Cessation
- 2010-05-04 UY UY0001038740A patent/UY38740A/es active IP Right Grant
- 2010-05-04 SI SI201032139T patent/SI3248610T1/sl unknown
-
2011
- 2011-10-25 IL IL215937A patent/IL215937A/en active IP Right Grant
- 2011-11-04 CL CL2011002768A patent/CL2011002768A1/es unknown
- 2011-11-15 ZA ZA2011/08371A patent/ZA201108371B/en unknown
- 2011-11-29 CR CR20110639A patent/CR20110639A/es unknown
- 2011-12-02 MA MA34406A patent/MA33716B1/fr unknown
- 2011-12-05 CO CO11167163A patent/CO6470863A2/es not_active Application Discontinuation
-
2012
- 2012-03-21 US US13/426,460 patent/US8835385B2/en active Active
- 2012-03-22 US US13/427,249 patent/US8795985B2/en active Active
- 2012-05-03 US US13/463,731 patent/US8618053B2/en active Active
-
2015
- 2015-10-22 PH PH12015502433A patent/PH12015502433A1/en unknown
- 2015-10-29 IL IL242377A patent/IL242377A/en active IP Right Grant
-
2018
- 2018-05-28 HK HK18106938.2A patent/HK1247134A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1247134A1 (zh) | Fgf21突變體及其應用 | |
ZA201103356B (en) | Fgf21 mutants and uses thereof | |
IL209395A0 (en) | Fgf21 mutants and uses thereof | |
IL210804A (en) | Benzylidenehydrazides and their uses | |
GB0808575D0 (en) | Compilign and linking | |
ZA201109034B (en) | Aminopyrrolidinone derivatives and uses thereof | |
GB0916578D0 (en) | Polypeptides and uses thereof | |
EP2483292A4 (fr) | Polypeptides lovd variants et leurs utilisations | |
GB0916576D0 (en) | Polypeptides and uses thereof | |
ZA201106702B (en) | Sceletium extract and uses thereof | |
GB0921001D0 (en) | Products and uses | |
ZA201103456B (en) | Leukolectins and uses thereof | |
EP2291377A4 (fr) | Imidazopyrimidinones et leurs utilisations | |
GB0903299D0 (en) | Composition and methods | |
HK1178526A1 (en) | Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof 8--7- | |
PL2247601T3 (pl) | Tiazopirymidynony i ich zastosowanie | |
GB0912744D0 (en) | Methods and uses | |
EP2408808A4 (fr) | Conjugués fonctionnalisés aux extrémités et leurs utilisations | |
ZA201008778B (en) | Fgf21 mutants and uses thereof | |
GB0909792D0 (en) | Composition and uses thereof | |
EP2291522A4 (fr) | Mutants de herg et leurs utilisations | |
GB0808857D0 (en) | Methdos and uses | |
GB0920904D0 (en) | Uses and methods | |
GB0902351D0 (en) | Bacteriophage and their uses | |
GB0810609D0 (en) | Methods and uses |